Figure 1.

Effectiveness of dupilumab in patients with atopic dermatitis: outcome measures over time during dupilumab treatment. All outcome measures have shown clinically relevant improvement with at least one unit of minimal clinically important difference. (a) The EASI score shows a rapid decrease with comparable trajectories in both countries, while Patient‐Reported Outcome Measures (PROMs) [(b) Patient‐Oriented Eczema Measure and (c) Numeric Rating Scale (NRS)‐Pruritus] showed different trajectories with relatively high scores and a clinically relevant, better outcome for PROMs in JP patients. (c) NRS‐Pruritus shows peak pruritus past 24 h (NL) and mean pruritus past 7 days (JP). (d) DLQI score in time during dupilumab treatment. (e) TARC levels after starting dupilumab treatment (in JP patients). Bands show 95% confidence intervals